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The concept of physiologically based pharmacokinetic (PBPK) modeling was introduced years ago, but it has not been practiced
signiﬁcantly. However, interest in and implementation of this modeling technique have grown, as evidenced by the increased
number of publications in this ﬁeld. This paper demonstrates brieﬂy the methodology, applications, and limitations of PBPK
modeling with special attention given to discuss the use of PBPK models in pediatric drug development and some examples
described in detail. Although PBPK models do have some limitations, the potential beneﬁt from PBPK modeling technique is
huge. PBPK models can be applied to investigate drug pharmacokineticsunder diﬀerent physiologicaland pathologicalconditions
or in diﬀerent age groups, to support decision-making during drug discovery, to provide, perhaps most important, data that can
save time and resources, especially in early drug development phases and in pediatric clinical trials, and potentially to help clinical
trials become more “conﬁrmatory” rather than “exploratory”.
1.Introduction
Although the concept of physiologically based pharmacoki-
netic (PBPK) modeling was introduced years ago, it has
not achieved the scope of development and implementation
that it deserves. Still, interest in and use of this modeling
technique have grown over the last few years, as evidenced
by the large increase in publications in this ﬁeld [1]. The
initiation of the Pediatric Exclusivity Program in the USA
andEuropemayalsocontributetowideruseofthismodeling
technique, as PBPK models can bridge pediatric and adult
pharmacology. The general concept of PBPK modeling is
to mathematically describe relevant physiological, physic-
ochemical, and biochemical processes that determine the
pharmacokinetic behavior of a compound in as much detail
as is appropriate or needed. In order to accomplish this,
principles of physiology and anatomy is employed to repre-
sent the species to be modeled as a structure composed of
physiologicallyrelevantcompartments,whereeachcompart-
ment often represents a single organ or tissue. Following the
anatomical structure of the organism, these compartments
are interconnected via the blood circulation loop, and the
mass-balance equations for each compartment describing
the fate of the substance within it are established. To solve
these equations, the PBPK model uses physiological and
substance-speciﬁc parameters. In the end, PBPK models can
describe and/or predict drug pharmacokinetics in certain
individuals, or under certain physiological or pathological
conditions,wheretheprimaryresultofasimulationisasetof
concentration-time curvesillustrating thetemporal behavior
of the drug in blood/plasma and/or other relevant organs.
Figure 1 illustrates the concept of building a PBPK model.
A number of articles reviewing PBPK modeling tech-
niques have been published; however, they cover the subject
from a diﬀerent perspective than this paper and/or possess a
diﬀerent aim and scope. Chen and Gross [2] and Himmel-
stein and Lutz [3] discuss the rationale and history behind
the development of PBPK models and report examples of
the ﬁrst PBPK models. Other reviews focus mainly on the
structure and methodology of PBPK modeling [1, 4, 5]
or on its implementation in certain areas—for example, to
guide research and development of new drugs [6], to predict2 Journal of Biomedicine and Biotechnology
drug pharmacokinetics in pediatric populations [7, 8], or to
predict drug interactions [9]. Even in articles that resemble
our way of approaching the subject, the limitations of
PBPK modeling are not clearly discussed, and either the
scope of the presented applications is diﬀerent [10], or less
emphasis is placed on demonstrating the potential use of
PBPK models to save time and eﬀort in pediatric drug
clinical investigations [11, 12]. Therefore, our objective is
to provide researchers and scientists who are interested
in using the PBPK modeling technique with a simpliﬁed
and general overview of the structure of PBPK models as
well as the various software packages that can be used in
model development. We have also highlighted some of the
technique’s weaknesses and provided an overview of its
various applications with an emphasis on recent examples
that show the potential of PBPK models, especially in
pediatric drug development where PBPK modeling arises as
a valuable method that can aid in conducting research in
children.
2.Discussion
2.1. PBPK Model Development. Generally, the ﬁve major
steps in PBPK model development include (1) specifying
general model structure, (2) specifying tissue model, (3)
writing model equations, (4) deﬁning model parameteriza-
tion, and (5) simulations and/or parameter estimation.
2.1.1. General Model Structure Speciﬁcation. PBPK models
emulate the structure of the living organism being studied
and represent the various organs and tissues as compart-
mentsinthemodelthatareconnectedviaabloodcirculation
loop which is subdivided into arterial and venous pools. The
natural basis for the choice of compartments is the available
data concerning the anatomy and physiology of the biologi-
calsystemfromthecellularleveltothewholebody. However,
this does not itself determine how many body regions, or
compartments, are needed, since the important aspects of
the drug’s pharmacokinetic events must be evaluated. The
choice also depends upon the model’s purpose and the
physicochemical (binding, lipid solubility, and ionization)
and pharmacological (mechanism of transport, site[s] of
action) properties of the modeled drug [14]. For example,
if the drug is not lipid soluble, the details of the adipose
tissues of the body are not particularly important; or if
only the absorption of the drug is of interest, then a model
that includes only those body tissues or organs involved in
t h ea b s o r p t i o np r o c e s sm a yb es u ﬃcient. The complexity
of the models and the amount of incorporated informa-
tion increase with the increasing number of represented
tissues/organs; however,duetothefactthatthemainfeatures
of drug distribution can often be described with models
that have surprisingly few details, a common strategy in
structuring PBPK models, called “lumping,” is implemented
[15, 16]. Tissues that share similar physiological, physico-
chemical, and biochemical properties are grouped as one
compartment, while tissues with distinct properties—such
as the liver, where metabolism occurs, or target tissues—are
separated from thelumpedcompartments. Eventually,PBPK
models do vary, ranging from partial-body PBPK models
which includecertain body systems ortissues, towhole-body
PBPK models where almost all body tissues are includedand
represented either as separated or lumped compartments.
2.1.2. Tissues/Organs Model Speciﬁcation. The model of each
particular tissue or organ must subsequently be speciﬁed
(i.e., subcompartments representing each organ/tissue must
be determined). The vast majority of PBPK models involve
one to four compartments for each tissue or organ. The
compartmentalization decisionis based onexisting informa-
tion regarding tissue kinetics and the biochemical process
involvedoncethedruggetsintothetissue [1].Itisimportant
todistinguishbetweenthediﬀerentassumptionsmadeatthis
level.A perfusion rate-limited tissue model is assigned under
the assumption that on entry with the blood circulation, the
drug distributes freely and instantly across the membranes
without diﬀusion barriers; thus, it is the rate of delivery
by the blood that is rate limiting. If diﬀusion barriers to
the distribution of a compound in the tissue are presumed
and can be physiologically identiﬁed—for example, capillary
membranes (such as the blood-brain barrier for some
hydrophilic molecules) or cellular membranes, or both—the
more complex permeability rate-limited tissue model will be
assigned with at least a two-compartment tissue structure.
Furthermore, the assumption of a well-stirred model is that
thereisnoconcentrationgradientwithinatissue/organcom-
partment. Thiscontrastswiththedispersionmodel,inwhich
ad i ﬀusion barrier cannot be identiﬁed but concentration
gradients nevertheless exist. Examples of a perfusion rate-
limited, well-stirred, one-compartment tissue model and a
permeability rate-limited, two-compartment tissue model
are given in Figure 2.
2.1.3. Writing the PBPK Model Equations. The PBPK model
equations are derived from the law of mass action—that is,
they are mass balance equations, as the kinetic processes
are mass transfer phenomena. Four types of mathematical
descriptions of the tissues within PBPK models have been
used [4, 15]: (i) algebraic descriptions, which are used
when the processes are assumed to equilibrate instantly
and can be considered static (e.g., alveolar and inhaled air
concentrations), (ii) linear ordinary diﬀerential, which are
themost commonlyused descriptions in describingdynamic
pharmacokineticprocesses,(iii)nonlinear diﬀerential,which
are used to represent non-linear processes within a partic-
ular tissue (e.g., concentration-dependent clearance and/or
binding),and(iv)partialdiﬀerential,whichareusedwiththe
dispersion tissuemodel.Figure 2s h o w se xa m plesofdi ﬀerent
diﬀerential equations that can be used in a PBPK model.
2.1.4. PBPK-ModelParameterization. Once model equations
are written, their parameters must be speciﬁed and/or esti-
mated. The parameters for incorporation into PBPK models
are generally either physiological or compound dependent.
Physiological parameters characterize the anatomical
structure and physiological processes of the species beingJournal of Biomedicine and Biotechnology 3
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C: Drug concentrations
Qorg: Organ blood ﬂow
P×SA: Permeability surface-area products
Korg: Organ/plasma partition coeﬃcient
Vmax, Km: Michaelis-Menten constants
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Figure 1: The concept for building a PBPK model modiﬁed according to Willmann et al. [13]. (a) Organisms (e.g., humans of diﬀerent
ages or populations) are the basis for the model. (b) The organism is divided into a number of compartments, each representing a single
organ.To describe thedistribution ofcompounds in thebody, theorgans are connected via their arteries andveins to the arterial andvenous
blood pool. Intercompartmental mass transport occurs via organ-speciﬁc blood ﬂow rates. The organs are mathematically connected. (c)
Division of each organ into three subcompartments representing the vascular space with blood cells and the interstitial and cellular space.
The interstitial space is assumed to be in direct contact with the plasma. The exchange of substances between the cellular and interstitial
compartment can occur by permeation across the membranes via passive diﬀu s i o na sw e l la sa c t i v ei n ﬂ u xa n de ﬄux transport processes
by saturable Michaelis-Menten (MM) kinetics with Vmax and Km as parameters. Metabolism of substances (Meta1 and Meta2) occurs
via active enzymes (MM kinetics). Finally, the model consists of a large number of coupled diﬀerential equations. (d) Output of the
model:concentration time curves for the substances shown are simulated and observed ciproﬂoxacin concentrations in various organs
after ciproﬂoxacin 5mg/kg was intravenously applied to a rat.4 Journal of Biomedicine and Biotechnology
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Figure 2: Diagrams and equations for a perfusion rate-limited, one-compartment model (a) and a permeability rate-limited, two-
compartment model with the permeability at the vascular membrane (b) of noneliminating organs, adapted from Nestorov et al. [15].
Q = blood ﬂow; C = concentration; V = volume; Kp = tissue:plasma distribution coeﬃcient; PS = permeability surface area coeﬃcient;
subscripts T,A R T ,V E N ,V, and EV indicate tissue, arterial, venous, vascular compartment, and extravascular compartment, respectively.
modeled, parameters such as organ/tissue volumes, cardiac
output and blood ﬂows, tissue composition, surface area,
pH values, and/or transit times for the gastrointestinal
tract. The values of these parameters are known to vary
among species and subjects or with age and physiologi-
cal/pathological state. Despite the large volume of available
literature reporting such physiological data in numerous
species—notably, annals of the International Committee on
Radiological Protection (ICRP) for human values [17]a n d
B r o w ne ta l .f o ra n i m a lv a l u e s[ 18]—allometric scaling (i.e.,
extrapolation from another species or another age group)
is still used when various physiological parameters that
are needed for a PBPK model are incomplete or entirely
lacking. Although physiological parameters are most often
assumedtobecompoundindependent,drugscansometimes
aﬀect the physiology of the biological system as seen, for
example, in the change of cardiac output and blood ﬂow
due to the induction of anesthesia [19, 20]. Therefore, the
potential pharmacological eﬀects of some compounds on
the physiological variables must be accounted for in such
circumstances.
The second set of parameters necessary for a PBPK
model are compound dependent and include information
such as permeability—surface area products (P × SA) and
partitioning of the substance between body tissues and the
blood/plasma (KpT). These parameters can be obtained
either from in vitro experiments, by extrapolating the
experimental in vivo values from animals to humans, or
by estimation/prediction using speciﬁc algorithms. A great
deal of specialized PBPK modeling software includes such
algorithms—for instance, those developed by Poulin and
Theil, Rodgers and Rowland, or Schmitt [21–23]t oc a l c u l a t e
tissue:plasma partition coeﬃcients. In the latter case, easily
obtainedcompoundcharacteristicssuch asmolecularweight
(MW), lipophilicity (logP or logD value), ionization (pKa
value), and plasma fraction unbound (fu) are alternative
inputs, as these algorithms use the previous information
along with tissue composition (lipids, proteins, and water)
to estimate partition coeﬃcients.
Clearance is a compound/species-speciﬁc parameter that
greatly inﬂuences the pharmacokinetic behavior of a drug;
thus, a measure of clearance is a necessary PBPK model
input. It is up to the researcher to decide how to provide the
PBPK model with this information. An experimental blood
or plasma clearance is often used as a direct input; however,
as many PBPK models are able to perform in vitro-in vivo
extrapolations (IVIVE), in vitro data can also be used—for
example, data from in vitro experiments on microsomes or
hepatocytes (in the form of half-lives or residual fractions).
In the latter case, depending on the type of input parameter,
PBPK models use additional information such as liver
volume, liver blood ﬂow, or microsomal binding to calculate
the in vivo hepatic intrinsic clearance.
2.1.5. PBPK Modeling Software for Simulation and Parameter
Estimation. I nt h el a s ts t e p ,t h ee n t i r es y s t e mi sc o u -
pled and equations that describe the model are coded
in a particular software language for subsequent parameter
estimation and/or simulation. Several commercial software
tools for developing PBPK models are available; however,
it is important to distinguish between general mathemati-
cal and engineering modeling software and specialized PBPK
modeling software packages. General modeling software
packages, such as MATLAB: [http://www.mathworks.com/
products/matlab/], ModelMaker: [http://www.modelkinetix
.com/modelmaker/],BerkeleyMadonna:[http://www.berke-
leymadonna.com/],andacslX,[http://www.acslX.com],pro-
vide a programming language for the model code, numerical
solutions for the ordinary diﬀerential equations that deﬁne
thesystembeingmodeled,and agraphicaloutputofthesim-
ulationresults.Thesesoftwarepackagesoﬀermuchﬂexibility
to the PBPK model developer, but more advanced modeling
and programming skills and experience are required; thus,
they are less suitable for beginners. However, both acslX
and Berkeley Madonna software attempt to incorporate
features to make them more intuitive for beginners by
providing, for example, a graphical interface and a PBPK
library to assemble models from already programmed code.
PK-Sim: [http://www.systems-biology.com/products/pk-sim
.html], Simcyp: [http://www.simcyp.com], and GastroPlus:
[http://www.simulations-plus.com], which are specialized
PBPK modeling software packages, provide less ﬂexibility inJournal of Biomedicine and Biotechnology 5
model development, but they also require less mathematical
and modeling experience. Such software tools provide the
user with either a click-and-drag assembly of the model
structure or an already built model, and can either simulate
particular PK-relevant processes (e.g., intestinal absorption
or metabolism) or constitute a generic whole body PBPK
model. Many oﬀer additional features; for example, Sim-
cyp and PK-Sim allow simulation of complex absorption,
distribution, metabolism, and excretion outcomes involving
multiple drug interactions and parent drug and metabolite
proﬁles. They also allow the simulation of virtual patient
populations such as obese/morbidly obese individuals and
patientswithrenal impairment orlivercirrhosis, and include
a clearance prediction model that incorporates knowledge
about growth, development, and maturation of various
organs and tissues involved in drug metabolism and elim-
ination across pediatric age groups to predict clearance in
children using adult values [13, 24, 25]. However, although
specialized PBPK modeling software packagesdo not require
programming skills as does general purpose software, they
are still relatively complex to use. This is not only due to
thediversityofinputoptionsandmany menus/windows that
require knowledge about these parameters, where they are
located, and how to work with them, but also because users
of such software tools should have a substantial background
knowledge of clinical pharmacology—for instance, pharma-
cokinetics topics as absorption, distribution, metabolism,
and the elimination processes of drugs as well as pharmaco-
geneticsand pharmacodynamics and also the molecular pro-
cesses involved in these topics—to understand the diﬀerence
among the various models oﬀered and the model equations
and assumptions so that the appropriate models are used to
conduct PK analysis.
2.2. PBPK Modeling Applications
2.2.1. Overview. Although PBPK modeling was originally
generated in the pharmaceutical ﬁeld, it has more appli-
cations in environmental toxicology and risk assessment
and has become a commonly and widely used technique.
However, PBPK modeling can be used for a variety of other
purposes and is becoming more popular in the ﬁelds of
pharmacology and drug development [6, 11, 12]. Even dur-
ing the early drug discovery programs and preclinical phase,
PBPK modeling can be used, together with in vitro data
and physicochemical characteristics, to anticipate the phar-
macokinetics of potential drug candidates in animals, which
may result in a reduction of unnecessary animal testing and
signiﬁcant timesavings [26].Anotherexampledemonstrated
the utility of a PBPK/pharmacodynamic model in the selec-
tion of the most promising compound from ﬁve potential
clinical candidates [27]. As PBPK models integrate relevant
information from various sources, including those that are
substance-dependent and physiologically relevant, they have
been widely used for in IVIVE of drug kinetics through
diﬀerent species or routes of administration [27–29]. The
PBPK-modeling technique has also emerged as a learning
tool that can help users understand the inﬂuence of diﬀerent
processes and/or parameters involved in determining drug
disposition and pharmacokinetic behavior [30]. PBPK-
modeling is widely used in describing and/or predicting
drugpharmacokinetic proﬁlesby simulating diﬀerentdosing
regimens that allows established therapies to be evaluated
and optimized. It also has been used to describe and/or
predict drug pharmacokinetics under diﬀerent physiological
and pathological conditions; for example, in pregnancy [31,
32], under surgery [33], and in liver cirrhosis [34, 35]. The
eﬀects of food [36], aging [37, 38], rest and physical exertion
[39–41], and genderdiﬀerences [42] have also been explored
using PBPK modeling. PBPK modeling can be used to
estimate the pharmacokinetics of both a parent drug and its
metabolite [43–45] and has been used successfully to predict
the magnitude of complex drug-drug interactions and to
clarify the change in drug pharmacokinetics upon concomi-
tant drug administration [46–48], which is important within
the pharmaceutical industry to improve safety and reduce
the attrition rate of new drugs. Additionally, PBPK models
are advantageous in that they enable prediction of exposure
to a drug and/or toxics in the plasma or blood, but also in
remote and/or inaccessible compartments such as the brain
[49]ortumortissues[50].Quantiﬁeddrugconcentrationsin
diﬀerenttissuesand/orbody ﬂuidsiseasy toobtainasoutput
when simulating and/or predicting using Simcyp or PK-Sim
modeling software.
Three relevant aspects of PBPK modeling are presented
in the following sections. Two examples are presented in
more detail demonstrating how a PBPK model can be mod-
iﬁed to describe drug pharmacokinetics under pathological
or altered physiological conditions. Section 2.2.4. focuses on
PBPK modeling in the pediatric population, with examples
showing how an adult PBPK model is modiﬁed to an age-
speciﬁc model to predict drug disposition in children and
how pediatric clinicaltrials canbeneﬁtfrom such amodeling
technique.
2.2.2. Predicting and/or Describing of Drug Pharmacokinetics
in Individuals with Disease. Physiological changes associated
with certain pathologicalconditions such as livercirrhosis or
renal insuﬃciency may aﬀect the pharmacokinetic behavior
of drugs. PBPK modeling emerges as a technique to predict
drug pharmacokinetics underthese conditions. One success-
ful example is the study by Edginton and Willmann [34], in
which they modiﬁed an existing “whole-body” PBPK model
by incorporating physiological diﬀerences between healthy
individuals and patients (changes in blood ﬂow, reduction
in plasma protein synthesis, reduced hepatic function, etc.)
to predict drug pharmacokinetics in patients with liver cir-
rhosis. They searched theliterature for quantitativemeasures
of these physiological changes and included the following
parameters: organ blood ﬂows, cardiac index, plasma bind-
ing proteins, hematocrit, functional liver volume, hepatic
enzymatic activity, and glomerular ﬁltration rate. Table 1
summarizes the input values as reported in the paper.
Finally, the modiﬁed model was used to predict the phar-
macokinetic parameters and plasma concentration proﬁles
for four compounds: alfentanil, lidocaine, theophylline, and
levetiracetam.Theresultswerethencomparedwithliterature
data and found to be adequate. Figures 3 and 4 show the6 Journal of Biomedicine and Biotechnology
Table 1: Physiological changes associated with liver cirrhosis
(Child-Pugh score A–C) presented as fraction of control values
from healthy individuals. The table is adapted from Edginton and
Willmann [34].
Parameter Child-Pugh class
ABC
Blood ﬂow
Portal 0.40 0.36 0.04
Hepatic arterial 1.3 2.3 3.4
Renal 0.88 0.65 0.48
Other organs 1.75 2.25 2.75
Cardiac index 1.11 1.27 1.36
Albumin 0.81 0.68 0.50
α1-acid glycoprotein 0.60 0.56 0.30
Hematocrit value 0.39 0.37 0.35
Functional liver mass 0.69 0.55 0.28
Hepatic enzymes◦
CYP3A4 1 0.4 0.4
CYP1A2 1 0.1 0.1
CYP2E1 1 0.83 0.83
GFR∗ 1 0.70 0.36
◦Fractions of control enzyme activity; CYP = cytochrome P450; ∗GFR =
glomerular ﬁltration rate.
simulation results for alfentanil and lidocaine, respectively.
The modiﬁed model presented in this study indicates the
ability of PBPK modeling to successfully account for altered
physiology, and thus altered pharmacokinetics, in diseases
when incorporating the eligible data. It can also serve as
a building block for creating a generic/global whole-body
PBPK model for the progressive disease of liver cirrhosis,
which may facilitate future simulations and prediction of
other drugs’ pharmacokinetics.
2.2.3. Predicting and/or Describing Drug Pharmacokinetics in
Individuals withAltered Physiology. Andrewetal.’s[32]study
investigated the ability of PBPK modeling to assess drug
pharmacokinetics in pregnant women. Midazolam was cho-
sen as the initial study drug, because it has been well studied
and prescribed during pregnancy. A coupled mother-fetus
PBPKmodel formidazolam wasdevelopedin MATLABwith
20 maternal and 16 fetal tissue compartments connected via
the placenta and fetal placental blood compartments. Model
equations and input physiological and drug-speciﬁc param-
eters used in the model development were not reported
in detail in this study; only their sources were mentioned.
To validate the developed model, model prediction and
observed data obtained from two studies for IV midazolam
administered to six women following caesarian section were
compared (Figure 5). Due to the lack of in vivo fetal data,
model validation was limited to the adult side. However,
despite limitations in the model validation, the developed
model could serve as a starting point for building a coupled
mother-fetus physiologically based model in humans to
assess the eﬀects of altered pharmacokinetics during preg-
nancy.
0.1
1
10
100
1000
A
l
f
e
n
t
a
n
i
l
p
l
a
s
m
a
c
o
n
c
e
n
t
r
a
t
i
o
n
(
μ
g
/
L
)
02468 1 0
Time (h)
Liver cirrhosis
Observed
Child-Pugh class B: predicted
Child-Pugh class C: predicted
Healthy controls
Observed
Predicted
Figure 3: Predicted and observed arithmetic mean (±SD) plasma
concentration-time curves of alfentanil in (a) healthy controls
and (b), (c) patients with liver cirrhosis. Figure is adapted from
Edginton and Willmann [34].
2.2.4. PBPK Modeling in Pediatric Populations. Interest in
in silico PBPK modeling in the ﬁeld of pediatric dug
development has been increasing since the initiation of the
Pediatric Exclusivity Program in 1997 by the US FDA that
was followed by the European Medicines Agency (EMA) in
[51]. This is because PBPK modeling arises as a useful tool
that can bridge pediatric and adult pharmacology. A child-
speciﬁc PBPK model can deliver information about age-
dependent pharmacokinetic changes of drugs in children,
explore “what if” scenarios to determine the most likely
cause of altered pharmacokinetics, and potentially help in
guiding pediatric clinical trials by suggesting, for example,
ﬁrst dose/dose range or optimal sampling times [5, 6].
Building a Pediatric PBPK Model to Perform Simulations and
Predict Drug Pharmacokinetics in Children. An u m b e ro f
pediatric PBPK models have been developed to predict drug
pharmacokinetics inchildren [52,55,56],oneofwhich isthe
modelpresentedbyEdgintonetal.[52].TheaimofEdginton
et al.’s study was to extend an existing adult PBPK model
to reﬂect age-related physiological changes in children from
birthtoageeighteen.Thisage-modiﬁedmodelwasthenused
together with a previously developed age-speciﬁc clearance
model topredictpediatric plasma concentrations. To dothis,
the researchers used data from the literature, including age-
dependent changes of the relevant physiological parameters
in children; for example, body weight, height, organ weights,
bloodﬂows, andinterstitial andvascularspace,tomodify the
adult model. Table 2 presents a sample of some physiological
parameters used. They then selected ﬁve drugs with already
available concentration-time proﬁles for both adults and
children: paracetamol, theophylline, levoﬂoxacin, alfentanil,
and morphine. First, the pharmacokinetic proﬁle of theseJournal of Biomedicine and Biotechnology 7
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Figure 4:Comparisonoflidocainepredicted andobservedmeanplasmaconcentration-timecurves inhealthycontrols(a)andpatientswith
Child-Pugh class A (b) and class C liver cirrhosis (c). Model simulation results adapted from Edginton and Willmann [34].
drugs was simulated in adults and compared with the data.
When the simulated curves in adults matched the data with
suﬃcient accuracy, a predicted pediatric clearance value
for each drug was generated using the clearance model
mentioned previously. Using this clearance value and the
age-modiﬁed model, pediatric plasma concentrations were
predicted. The predicted plasma concentration-time curves,
volume of distribution (Vd), and half-life (t1/2)w e r ec o m -
pared with thecorresponding observedvaluestoevaluatethe
accuracy of model predictions. Figure 6 provides an example
of how well the predicted versus observed plasma concen-
trations for two drugs correlate. Another recent publication
discussed a similar use of PBPK models in which Simcyp
software was used to predict drug pharmacokinetics in
children under various situations by performing simulations
to replicate published pediatric clinical trials [7]. The same
publication presented an interesting example, as a pediatric
model was used to simulate a complex drug interaction
scenario with a virtual 2-year-old child who was a patient in
a pediatric intensive care unit. This pediatric model was used
to investigate the eﬀects of the interacting drugs in combi-
nation with midazolam pharmacokinetics. The simulations
were able to show the eﬀect on the plasma concentrations of
midazolam (CYP 3A4 substrate) upon sequential adding of
rifampicin (CYP 3A4 inducer), rifampicin and ﬂuconazole
(CYP 3A4 inhibitor), and rifampicin, ﬂuconazole, and
clarithromycin (CYP 3A4inhibitor). This example illustrates
the ability of PBPK modeling to address complex clinical
drug-druginteractionsandtoexplore“what if”scenarios. As
a next step, these models need to be validated by prospective8 Journal of Biomedicine and Biotechnology
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Figure 5: Simulated midazolam maternalplasma concentration-time proﬁle following postcaesarean IV bolus compared with two diﬀerent
set of observed data; adapted from Andrew et al. [32].
Table 2: Values of organ blood ﬂows, portal blood ﬂow, total hepatic blood ﬂow (QH), bodyweight, and height that were used in the PBPK
model developed and reported by Edginton et al. [52].
Parameter New born 1y 5y 10y 15y Adult (30y)
Organ blood ﬂow (mL/min)
Adipose 30 12 171 250 315/484
a 325/502a
Brain 180 700 900 840/750a 805/708a 780/708a
Gonads 0.3 0.6 1.7/0.7
a 2.5/1.0
a 3.2/1.1
a 3.3/1.2
a
Heart 24 48 136 200 252/285
a 260/295
a
Kidneys 110 230 577 854 1335/950a 1325/1120a
Large intestine 24 48 136 200 251/285a 260/295a
Liver 39 78 221 325 409/370
a 423/383
a
Muscle 31 72 212 429 941/646
a 1105/665
a
Pancreas 6 12 34 50 63/57a 65/59a
Skeleton 30 60 170 250 315/285a 325/295a
Skin 30 60 170 250 315/285a 325/295a
Small intestine 60 120 340 500 630/627
a 650/649
a
Spleen 18 36 102 150 189/171
a 195/177
a
Stomach 6 12 34 50 63/57a 65/59a
Portal blood ﬂow (mL/min) 114 228 646 950/950a 1197/1197a 1235/1239a
QH (mL/min)∗ 153 306 867 1275/1273
a 1600/1566
a 1660/1620
a
Body weight (kg) 3.5 10 19 32 56/53
a 73/60
a
Height (cm) 51 76 109 138 167/161a 176/163a
a = Male/female; ∗QH = total hepatic blood ﬂow.
pharmacokinetic data in children as an ultimate proof of
their accuracy. Having qualiﬁed the models in such a way,
“what if” scenarios could be simulated to support future
trial designs or even guide individual drug treatments. In
addition, developing and validating such pediatric PBPK
models is important because of their potential to explore the
pharmacokinetics of drugs for which little or no pediatric
data are available.
Using thePediatric PBPKModeltoSuggestDosinginChildren.
An example of how a pediatric PBPK model can be used
to suggest age-speciﬁc doses for sildenaﬁl was presented byJournal of Biomedicine and Biotechnology 9
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Figure 6: Predicted dose-normalized pediatric plasma concentration-time curves (lines) versus observed data (symbols) for (a) alfentanil
and(b)morphineasreported inthe originalstudy by Edgintonet al.[52].Observed datawasobtained from variousstudies inthe literature.
Hsien [53]. Hsien developed and validated, in the same way
as mentioned previously, a PBPK model for sildenaﬁl in
adults.Aclearancescaling modulewas also used with anage-
modiﬁed PBPK model to predict plasma concentrations of
sildenaﬁl in children that could supplement the very few
pediatric pharmacokinetic data available in literature so far.
The pediatric PBPK model of sildenaﬁl was used to run
simulations in virtual pediatric populations of diﬀerent ages
to estimate the exposure after a weight-normalized dose
according to adult data. The simulation results showed that
after 3 months of age, the exposure of the same weight-
normalized dose across the pediatric age groups increased as
the age of children increased and, therefore, that age-speciﬁc
dose adaptation is necessary to achieve a relatively con-
stant drug exposure in adults and children (Figure 7). The
suggested dosing adjustments across pediatric age groups
in this example of sildenaﬁl have yet to be validated with
prospectively collected data and are, therefore, hypothetical.
Nevertheless, upon establishing and validating the use of
PBPK modeling for this purpose, the provided data may
help clinical trials become more “conﬁrmatory” rather than
“exploratory,”and thusthe modeling exercise will potentially
save time, eﬀort, and the number of trials needed to be
performed in children.
Using the Pediatric PBPK Model to Suggest Sampling Times.
Willmann [54] provides an example of using a PBPK model
to determine optimal sampling times in children, com-
paring the possible diﬀerence between suggested pediatric
sampling times based on adult concentration-time data
and suggested sampling times based on simulations by a
PBPK model (Figure 8). The latter, as shown in the study,
can potentially help detect the best sampling times for a
pharmacokinetic analysis and avoid taking blood samples
where drug concentration is out of detection range. This
is of great importance, especially in neonates and infants,
as taking blood samples is more diﬃcult than in adults
and a main challenge in conducting pediatric clinical trials.
The primary reason for using a PBPK model to provide
such information in advance is to help conduct these trials
optimally. Whether these techniques can reduce the number
of children required for clinical trials and, therefore, save
time,eﬀort,andcostremains tobeproven.Finally,itisworth
mentioning that the ultimate gold standard is prospectively
validating predictions/simulations generated by pediatric
PBPK models. To our knowledge, in vivo data for validation
up to now had been collected before the predictions of the
models had been made. To qualify a model ultimately, data
should be collected after predictions had been made and
then compared. Unfortunately, there is a deﬁnite shortage
of clinical examples that verify the use of PBPK models
prospectively; such examples need to be developed to gain
conﬁdence in using PBPK models in clinical situations.
2.3. Limitations of PBPK Modeling. PBPK modeling requires
comprehensive data about the physiological, biochemical,
and physicochemical processes that occur in biological
systems indiﬀerentagegroupsorundercertainphysiological
and pathological conditions. These data are not available
from only one source, which may lead to some confusion
and to a problem in establishing a reliable source of accurate
and consistent information. PBPK models reﬂect current
scientiﬁc knowledge, and while some processes are known
to be well characterized, others are partly or poorly char-
acterized, as information gaps may exist. Information gaps
or poor characterization of some physiological processes,10 Journal of Biomedicine and Biotechnology
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Figure 7: Simulation results using the PK-Sim software of a PBPK
model for sildenaﬁl in children [53]. (a): Predicted age-dependent
sildenaﬁl hepatic clearance across diﬀerent pediatric ages based on
the clearance scaling module in PK-Sim software. (b): Age-related
doses for oral sildenaﬁl in children depending on the simulated
age-related exposure (not shown) of sildenaﬁl in a virtual pediatric
population and the estimated exposure of the estimated doses of
sildenaﬁl in children between 3 months and 18 years. Potential
pediatric doses based on simulations for sildenaﬁl to achieve adult
exposure: infants and children from 3 months to 4 years: 0.8mg/kg;
children from 5 to 8 years: 0.5mg/kg; and children older than 8
years: 0.35mg/kg as in adults. Box plots represent median, 25th,
and 75th percentiles (box), 5th and 95th percentiles (error bar),
and maximum and minimum values (x)o fA U C 0−∞ from 1000
simulationsin each age group.
such as transporters’ abundance or the absorption process
in newborns and infants, may cause the model to fail to
optimally describe the pharmacokinetic behavior of some
drugs in such population. Therefore, it is important to
emphasize that the validity and quality of the simulations
depends on the corresponding model and its incorporated
data as well as its purpose, and uncertainty concerning the
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Figure 8: Schematic drawing of a potential application of PBPK
simulations for children of diﬀerent ages to ﬁnd optimal blood
sampling time points for the pharmacokinetic investigations in a
future pediatric trial according to Willmann [54]. Arrows indicate
optimal sampling time for a 3-year-old child, a newborn, and an
adult. LOQ:limit of quantiﬁcation.
data used to build the model should be properly reﬂected.
Moreover, as simulations are associated with prediction
errors and uncertainty, they require accurate judgment and
interpretation of their inferences to frame them in the right
context. In addition, simulation results should be supported
by experimental data, and should not be used to replace data
from well conducted studies as primary degree of evidence
[57]. Care should be given to the fact that poor quality
modeling and simulations practices could lead to a biased
model or overestimation of the predictive power of the
model. An extensive and continuous evaluationofthe model
will help minimize and identify early the biased models.
Finally, the researcher/user of this modeling technique
should understand the physiological and pharmacological
rationale behind the model and should be aware that
PBPK modeling, despite its potential beneﬁts and various
implementations, doesnot providetheultimate solutionand
that there remains a shortage of prospective examples that
verify that this technique is as good in clinical practice as in
theory.
3.Conclusion
This paper provides a brief overview that covers the method-
ology, applications and limitations of PBPK modeling with
special attention given to discuss use of PBPK models in
pediatric drug development with some examples described
in detail. The applications of the PBPK modeling technique
are diverse, as PBPK models can potentially be used at diﬀer-
ent stages of drug development from early discovery phases
and preclinical development up to clinical phase studies.
Simulations by PBPK models are developed to potentially
save time and eﬀort, to explore the eﬀect of various factors
on drug pharmacokinetics, to address the magnitude of
drug-drug interactions, and to help optimize conductance
of clinical trials in special populations such as pediatrics,
where optimal planning is needed to minimize the ethicalJournal of Biomedicine and Biotechnology 11
andtechnical diﬃcultiesand is,therefore,an essential keyfor
success. However, prospective examples that assure the clin-
ical value of such a modeling technique are needed and are
important to increase the acceptance of these techniques in
the planning phases of clinical trials or for the practice of the
individual drug treatment. PBPK models do have limitations
and weaknesses. For instance, because they reﬂect current
scientiﬁcknowledge,somephysiologicalprocessesarepoorly
characterized and information gaps may exist. In addition,
the validity of the simulations dependson the corresponding
model and its incorporated data, and obtained results are
associated with prediction errors and uncertainty. The use
of PBPK modeling technique is still relatively narrow, but
the introduction of many universally applicable software
tools with a more user-friendly interface that do not require
an extensive modeling and/or mathematical background
have facilitated its use and contributed signiﬁcantly to its
wider implementation in diﬀerent scientiﬁc areas over the
last few years. Researchers need, however, to have a sub-
stantial background knowledge of clinical pharmacology,
pharmacokinetics, and pharmacodynamics as well as the
molecular processes involved in these topics to understand
the diﬀerence among the various models oﬀered and the
model equations and assumptions so that the appropriate
models are used to conduct PK analysis and to accurately
interpret and judge the results.
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